Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON
  1. Home
  2. Azioni
  3. Finlandia
  4. Nasdaq Helsinki
  5. Orion Oyj
  6. Notizie
  7. Altre lingue
    ORNBV   FI0009014377

ORION OYJ

(ORNBV)
Prezzo in differita. Tempo differito Nasdaq Helsinki - 22/10 17:29:53
36.75 EUR   +1.21%
20/10Orion Oyj fornisce una guida agli utili per l'anno 2021
CI
17/09Il presidente e amministratore delegato di Orion andrà in pensione nel 2022
MT
26/03ORION OYJ: Data ex dividendo perdividendo finale
FA
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietàFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su ORION OYJ
21/10ALLIGATOR BIOSCIENCE AB: Interim report January-September 2021
20/10ORION OYJ: Group Interim Report 1–9/2021
20/10Orion Oyj Provides Earnings Guidance for the Year 2021
20/10Orion Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended Septembe..
08/10ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
05/10ORION OYJ: publishes Interim Report for January–September 2021 on Wednesday 20 Octo..
17/09ORION OYJ: President, CEO To Retire In 2022
17/09ORION OYJ: Successor plan of the President and CEO of Orion
17/09Timo Lappalainen to Retire as President of Orion Corporation in 2023
17/09Timo Lappalainen to Retire as CEO of Orion Corporation in 2023
14/09ORION OYJ: 90,889 Orion Corporation A shares converted into B shares
25/08ORION CORPORATION: Managers' transactions – Kari Jussi Aho
19/08BIOSTOCK: Alligator Bioscience enters collaboration with Orion Corporation
18/08ALLIGATOR BIOSCIENCE: announces Immuno-oncology Research Collaboration and License Agreem..
18/08ORION OYJ: Corporation and Alligator Bioscience announce immuno-oncology research collabo..
18/08Orion Corporation and Alligator Bioscience Announce Immuno-Oncology Research Collaborat..
17/08ORION OYJ: will remain as the owner of pharmaceutical manufacturing plant in Kuopio, Finl..
03/08ORION OYJ: Secures Contract To Market, Distribute Marinus' Ganaxolone
03/08ORION OYJ: Corporation signs European wide marketing and distribution agreement with Mari..
23/07ORION CORPORATION: Managers' transactions – Liisa Hurme
21/07ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
19/07ORION OYJ: Maintains Lower Net Sales Guidance for FY21
19/07ORION OYJ: Group Half-Year Financial Report 1-6/2021
19/07Orion Oyj Provides Earnings Guidance for the Year 2021
19/07Orion Oyj Reports Earnings Results for the Second Quarter Ended June 30, 2021
19/07ORION OYJ: Corporation's financial reporting and Annual General Meeting in 2022
19/07ORION OYJ: Corporation's financial reporting and Annual General Meeting in 2022 
15/07ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
12/07ORION OYJ: Initiates Recall of Dietary Supplement on High Chemical Levels
12/07ORION OYJ: recalls Multivita Forte dietary supplement from consumers
12/07Orion Oyj Recalls Multivita Forte Dietary Supplement from Consumers
08/07ORION OYJ: 32,884 Orion Corporation A shares converted into B shares
02/07ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
02/07ORION OYJ: publishes Half-Year Financial Report for January–June 2021 on Monday 19 ..
28/06ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
23/06ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
21/06ORION OYJ: Animal Health's Dog Anxiety Therapy Wins EU Committee's Positive Opinion
21/06ORION OYJ: Animal Health's Tessie® (tasipimidine) receives positive CVMP opinion
21/06Orion Animal Health’s Tessie® (tasipimidine) Receives Positive CVMP Opinion
17/06ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
09/06ORION OYJ: Shares Positive Result Of Virtual Reality Therapy DTxP
09/06ORION OYJ: Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using V..
09/06Orion Corporation’s Clinical Trial Shows Significant Improvement for Chronic Pain Patie..
08/06ORION OYJ: Teams Up With Finnish Red Cross Blood Service to Develop Cell Therapies for Ca..
08/06ORION OYJ: and the Blood Service launch collaboration to develop new CAR T-cell cancer th..
08/06Orion Corporation and the Blood Service Collaborates to Develop New CAR T-Cell Cancer T..
27/05ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
26/05ORION OYJ: Virtual Capital Markets Day today at 13.00 EEST – presentation material ..
25/05ORION OYJ: Mulls Sale of Pharmaceutical Manufacturing Site in Finland
25/05ORION OYJ: to investigate possible sale of its pharmaceutical manufacturing plant in Kuop..
19/05ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
17/05ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
17/05ORION OYJ: Animal Health Lands Positive Opinion From European Medicines Agency For Anxiet..
17/05ORION OYJ: Animal Health's Bonqat® (pregabalin) receives positive CVMP opinion
17/05Orion Animal Health’s Bonqat® Receives Positive CVMP Opinion
11/05ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
05/05ORION CORPORATION: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
05/05ORION CORPORATION: Managers' transactions – Mikael Silvennoinen
05/05ORION CORPORATION: Managers' transactions – Timo Maasilta
05/05ORION CORPORATION: Managers' transactions – Pia Kalsta
05/05ORION CORPORATION: Managers' transactions – Kari Jussi Aho
05/05ORION CORPORATION: Managers' transactions – Ari Lehtoranta
05/05ORION CORPORATION: Managers' transactions – Hilpi Rautelin
05/05ORION CORPORATION: Managers' transactions – Veli-Matti Mattila
05/05ORION CORPORATION: Managers' transactions – Eija Ronkainen
04/05ORION OYJ: Invitation to Orion's Virtual Capital Markets Day on 26 May 2021
27/04CORRECTION: Composition of the Nomination Committee of Orion Corporation
27/04ORION OYJ: Composition of the Nomination Committee of Orion Corporation
27/04Orion Corporation Announces Composition of the Nomination Committee
27/04ORION OYJ: Finnish drugmaker Orion first-quarter profit beats forecast
27/04ORION OYJ: Group Interim Report 1-3/2021
27/04Orion Oyj Provides Earnings Guidance for the Year 2021
27/04ORION OYJ: Targets Carbon Neutrality By 2030
27/04ORION OYJ: aims to achieve carbon neutrality by 2030
12/04ORION OYJ: publishes Interim Report for January–March 2021 on Tuesday 27 April 2021
1  2  3  4  5  6  7  8Pross.
Prossimi eventi del settore